Back to Search Start Over

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study